• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Theramex wins decentralized procedure approval in EU, UK for hormone drug

March 3, 2021 By Sean Whooley

TheramexTheramex announced today that it received decentralized procedure approval in several EU countries and the UK for its Bijuva capsules.

Bijuva possesses an indication for continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses, according to a news release.

London-based Theramex, formerly the women’s health business arm of Teva Pharmaceuticals, said Bijuva is the first and only oral combined HRT with bio-identical hormones to be made available to patients across Europe. It is being made available through a license agreement signed with TherapeuticsMD in 2019 that granted Theramex the exclusive license and supply rights for Bijuva outside the U.S., Canada and Israel.

“Up to 80% of women experience vasomotor symptoms during their menopause transition, and these lasted more than 7 years for more than half of the women,” Theramex CEO Robert Stewart said in the release. “With Bijuva, Theramex aims to help these patients with an oral combination of low dose estradiol and progesterone which have the same chemical and molecular structure as the hormones produced naturally in a woman’s body.”

Decentralized procedure approval can be used for medicines that do not need to be authorized by the centralized procedure and have not already been authorized in any member state of the EU.

Filed Under: Featured, Regulatory/Compliance, Women's Health Tagged With: Theramex

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS